Octreotide

Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly[1][2].

Product Specifications

CAS Number

[83150-76-9]

Product Name Alternative

SMS 201-995

UNSPSC

12352209

Hazard Statement

H315, H319, H320

Target

Apoptosis; Somatostatin Receptor

Type

Peptides

Related Pathways

Apoptosis; GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Octreotide.html

Purity

99.96

Solubility

H2O : ≥ 50 mg/mL

Smiles

O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=CC=C3)N[C@@H]1CC4=CNC5=CC=CC=C45

Molecular Formula

C49H66N10O10S2

Molecular Weight

1019.24

Precautions

H315, H319, H320

References & Citations

[1]Wang XX, et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet?induced obesity. Mol Med Rep. 2017 Jul;16 (1) :109-118|[2]Kugita M, et al. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One. 2017 May 18;12 (5) :e0177934.|[3]Xiao-Xia Wang, et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet‑induced obesity. Mol Med Rep. 2017 Jul;16 (1) :109-118.

Shipping Conditions

Blue Ice

Storage Conditions

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

Scientific Category

Peptides

Clinical Information

Launched

Isoform

SSTR2; SSTR3; SSTR5

Citation 01

Basic Clin Pharmacol Toxicol. 2022 Sep;131 (3) :174-188.|Biomacromolecules. 2024 May 13;25 (5) :2749-2761.|Cell Mol Bioeng. 2022 Dec 22;16 (1) :55-67.|Eur J Nucl Med Mol Imaging. 2024 Nov;51 (13) :4099-4110.|Faculty of Biological and Environmental Sciences. University of Helsinki Finland. 2018 Dec.|J Pharm Biomed Anal. 2022 Mar 20:211:114518.|J Pharm Biomed Anal. 2023 Feb 5:224:115156.|J Pharm Sci. 2022 Dec;111 (12) :3417-3423.|Mol Cancer. 2024 Sep 20;23 (1) :205.|J Biol Chem. 2025 Jul 30;301 (9) :110544.|Mol Med Rep. 2024 Jun;29 (6) :90.|Nat Commun. 2023 Feb 21;14 (1) :962.|Patent. US20240307504A1.|Research Square Print. 2022 Aug.